ApprovedApproved
Celcuity (CELC) · Oncology
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
Marketer take: Labeled for HR+/HER2- breast cancer without a PIK3CA mutation, a different slice of post-endocrine disease than PI3K-pathway drugs aimed at mutated tumors, so biomarker results will steer the oncologist conversation.
Source: FDA page · Last verified Nov 15, 2026